Antonio Gonzalez Martin, Kasumi Yamamoto, Xiaohua Wu, Tsukasa Baba, Destin Black, Scott Jordan, Akira Kikuchi, Eiji Kondo, Satoru Nagase, Shu Soeda, Takashi Uehara, Lin-Hung Wei, Mayu Yunokawa, Veronica Mariotti, Laura-Carolin Hasenkamp, Steven Hua, Hanan Abdel-Monem, David Shao Peng Tan, Joyce F. Liu, Kosei Hasegawa. "Trastuzumab deruxtecan (T-DXd) + bevacizumab (BEV) as first-line (1L) maintenance therapy in patients (pts) with human epidermal growth factor receptor 2 (HER2)–expressing ovarian cancer (OC): Results from the DESTINY-Ovarian01 (DO-01/ENGOT-ov89/GOG-3112/APGOT-OV13) safety run-in (SRI).." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.5554